Amgen (AMGN) Accounts Payables (2009 - 2026)

Amgen (AMGN) has reported Accounts Payables for 18 consecutive years, with $2.9 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables rose 21.99% year-over-year to $2.9 billion; the TTM figure through Mar 2026 stood at $2.9 billion (up 21.99% YoY), while the FY2025 annual figure was $2.4 billion, up 24.06% from the prior year.
• Accounts Payables came in at $2.9 billion for Q1 2026 at Amgen, up from $2.4 billion in the prior quarter.
• The five-year high for Accounts Payables was $3.0 billion in Q2 2025, with the low at $1.2 billion in Q3 2022.
• Average Accounts Payables over 5 years is $1.9 billion, with a median of $1.6 billion recorded in 2024.
• Across the five-year window, Accounts Payables slipped 5.92% in 2023 and jumped 87.05% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $1.6 billion in 2022, then advanced by 1.15% to $1.6 billion in 2023, then grew by 20.0% to $1.9 billion in 2024, then rose by 24.06% to $2.4 billion in 2025, then advanced by 24.0% to $2.9 billion in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $2.9 billion, $2.4 billion, and $2.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.